Skip to main content
Porto

PMMNG logo

  • Home
  • News
  • Our Meetings
    • Monthly PMMNG Meetings
    • Steering Committee Meetings
  • Myeloma Events
    • Upcoming Events
    • Archived Myeloma Events
  • Our Members
  • Miles for Myeloma
  • Resources
    • Myeloma Education Resources
    • Myeloma and Cancer Foundations
    • Regional Myeloma Support Groups
    • Publications and Newsletters
    • Cancer Support Networks
    • Treatments
    • Financial Assistance
    • Caregivers
  • Clinical Trials

Archived Events
  • IMF: Best of 2021 ASCO & EHA
  • MMRF: Latest Updates on Minimal Residual Disease (MRD)
  • July 2021 Meeting: Interpreting Lab Results
  • CancerCare: What’s New in Precision Medicine
  • CureTalks: CRISPR-edited Immune Cells Enhance Fight Against Blood Cancers
  • CancerCare: Transplantation as a Treatment Option for Blood Cancers
  • MMRF: ASCO Highlights Webinar
  • CancerCare: Caring for Your Loved One with Cancer
  • CancerCare: Managing the Side Effects of Immunotherapy
  • CancerCare: What’s New in Diagnostic Technologies for People Living with Blood Cancers

MMRF: New Drug Approval: PEPAXTO®

MMRF logoWhat:  Webcast video (1:04:34)
When: Thursday, April 1, 2021 6:00-7:00 PM (ET)
Where: Web

Access webcast video Access webcast slides

Tags
event
archived
webcast
mmrf
treatment
pepaxto
melflufen
melphalan flufenamide
antibody drug conjugates
side effects
clinical trial data
Dr. Paul G. Richardson
Dr. Peter Voorhees